Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 2,650,000 shares, a growth of 21.6% from the July 31st total of 2,180,000 shares. Approximately 12.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 800,600 shares, the days-to-cover ratio is presently 3.3 days.

Institutional Investors Weigh In On Agenus

Institutional investors and hedge funds have recently modified their holdings of the business. RPO LLC bought a new position in Agenus in the 4th quarter valued at $43,000. Point72 DIFC Ltd bought a new position in shares of Agenus in the second quarter worth about $51,000. Ables Iannone Moore & Associates Inc. purchased a new position in Agenus in the 4th quarter worth about $65,000. Vanguard Personalized Indexing Management LLC bought a new stake in Agenus during the 4th quarter valued at about $95,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Agenus during the 2nd quarter valued at about $106,000. 61.46% of the stock is owned by institutional investors.

Agenus Trading Down 2.3 %

Shares of AGEN opened at $4.99 on Friday. The company’s fifty day simple moving average is $9.37 and its 200-day simple moving average is $11.27. The company has a market cap of $104.79 million, a P/E ratio of -0.39 and a beta of 1.33. Agenus has a twelve month low of $4.41 and a twelve month high of $28.90.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The company had revenue of $23.51 million for the quarter, compared to the consensus estimate of $64.73 million. During the same quarter in the prior year, the business earned ($4.00) earnings per share. Analysts predict that Agenus will post -10.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Robert W. Baird cut Agenus from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $8.00 in a report on Friday, July 19th. William Blair lowered shares of Agenus from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 18th. Baird R W cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $7.00 price target (up previously from $3.00) on shares of Agenus in a research report on Friday, July 19th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.50.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.